Comparison of requirements for deep neuromuscular block effect during continuous and intermittent bolus injection of rocuronium in patients under general anesthesia

Comparison of requirements for deep neuromuscular block effect during continuous and intermittent bolus injection of rocuronium in patients under general anesthesia: a randomized equivalence trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0006904

Enrollment

Registered

2022-01-07

Start date

2022-01-11

Completion date

Unknown

Last updated

2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : Deep neuromuscular block during surgery according to Rocuronium injection method : In both groups, the goal of deep neuromuscular block is to maintain a post-tetanic count (PTC) of 3 or l

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients aged 18-65 years 2) Patients undergoing general anesthesia for elective abdominal (gastrointestinal tract, colon and rectal, liver) surgery 3) Patients whose operation time is expected to be more than 2 hours 3) Patients corresponding to American Society of Anesthesiologist Status 1-2

Exclusion criteria

Exclusion criteria: 1) Patients under total venous anesthesia 2) Emergency surgery patients 3) body mass index = 30 kg/m2 4) Pregnant and lactating women 5) Patients with lung diseases such as asthma and COPD 6) Patients with a history of treatment for cerebrovascular disease 7) Patients allergic to drugs (including neuromuscular blocking agent): - Patients with a history of hypersensitivity to sevoflurane, desflurane, or other halogenated anesthetics. - Patients with a history of hypersensitivity to remifentanil and other fentanyl analogues all. - Patients with a history of hypersensitivity to rocuronium and any of its components or neuromuscular blockers 8) Patients with kidney disease (patients with creatinine clearance less than 60ml/min, patients with renal impairment with a baseline blood creatinine value of 1.5 mg/dL or more) 9) Patients with liver dysfunction 10) Patients with neuromuscular junction disease, including patients with myasthenia gravis and myasthenia gravis 10) Patients who have difficulty in voluntary consent; 11) Patients with a history of psychiatric disorders, including those with difficulty in normal communication 12) Past and family history of malignant hyperthermia or allergy to drugs administered during general anesthesia, and taking drugs known to interact with rocuronium during surgery (some antibiotics, metronidazole, also phenytoin and carbamazepine, diuretics, monoamine oxidase inhibitors, calcium channel blockers, corticosteroids, and those containing magnesium ions). 13) Patients with a history of difficult endotracheal intubation

Design outcomes

Primary

Measure	Time frame
Total amount of rocuronTotal rocuronium dose for deep neromuscular relaxation during surgery	—

Secondary

Measure	Time frame
Muscle recovery pattern after cessation of rocuronium administration;Time elapsed from administration of muscle relaxation reversal agent to extubation of the endotracheal tube	—

Countries

Korea, Republic of

Contacts

Public ContactJu Deok Kim

Kosin University Gospel Hospital

uamyfriends@hanmail.net+82-51-990-6474

Outcome results